Source:http://linkedlifedata.com/resource/pubmed/id/11895791
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2002-3-15
|
| pubmed:abstractText |
Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de l'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55%) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44%) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:BathP EPE,
pubmed-author:BertoniFrancescoF,
pubmed-author:BiondiAndreaA,
pubmed-author:CapellaCarloC,
pubmed-author:CavalliFrancoF,
pubmed-author:CazzanigaGiovanniG,
pubmed-author:ConconiAnnaritaA,
pubmed-author:CotterFinbarr EFE,
pubmed-author:GiardiniRobertoR,
pubmed-author:HancockBarry WilliamBW,
pubmed-author:MottaTeresioT,
pubmed-author:NoveroDomenicoD,
pubmed-author:PedrinisEnnioE,
pubmed-author:PonzoniMaurilioM,
pubmed-author:RinaldiPaoloP,
pubmed-author:SmithPaulP,
pubmed-author:SouhamiRobertR,
pubmed-author:United Kingdom Lymphoma Group,
pubmed-author:WotherspoonAndrewA,
pubmed-author:ZuccaEmanueleE
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
99
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2541-4
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11895791-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11895791-Chlorambucil,
pubmed-meshheading:11895791-Disease-Free Survival,
pubmed-meshheading:11895791-False Negative Reactions,
pubmed-meshheading:11895791-Follow-Up Studies,
pubmed-meshheading:11895791-Helicobacter Infections,
pubmed-meshheading:11895791-Helicobacter pylori,
pubmed-meshheading:11895791-Humans,
pubmed-meshheading:11895791-Immunoglobulin Heavy Chains,
pubmed-meshheading:11895791-Lymphoma, B-Cell, Marginal Zone,
pubmed-meshheading:11895791-Neoplasm, Residual,
pubmed-meshheading:11895791-Polymerase Chain Reaction,
pubmed-meshheading:11895791-Reproducibility of Results,
pubmed-meshheading:11895791-Time Factors
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial.
|
| pubmed:affiliation |
Department of Experimental Haematology, Barts and The London-Queen Mary's School of Medicine and Dentistry, London, United Kingdom. frbertoni@tin.it
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|